Abstract:A prospective phase II trial was conducted to investigate the diagnosis of leptomeningeal metastases (LMs) and clinical outcomes of comprehensive treatment. Patients who were clinically suspected to have LMs and received comprehensive treatment based on tomotherapy were enrolled. Whole brain radiotherapy (WBRT) with or without simultaneously boost to LM or craniospinal irradiation (CSI) was given to them. The diagnosis and response were assessed by the results of enhanced MRI, clinical signs and symptoms, cerebrospinal fluid (CSF) cytology and liquid biopsy and liquid genomics detection. The primary endpoint was local control (LC), and the secondary endpoints were intracranial progression-free survival (IPFS) and overall survival (OS). Kaplan-Meier method was used. From 2014 to 2017, 88 patients were enrolled (Male: Female=36:52), and the median age was 55 years old (range, 29-81). The major primary diagnosis was non-small cell lung cancer (64.8%). Typical clinical signs included cerebral (70.5%), cranial nerve palsies (30.7%), and spinal complaints (33.0%). 20.5% of patients showed no obvious symptoms. MRI findings before treatment included 4 types: multiple brain metastases (BMs) with focal LMs, large BMs invaded meningeal, extensive LMs and LMs proved by clinical symptoms or CSF without changes in MRI. The lesions appeared as nodular (67.1%), linear enhancement (18.2%), both (10.2%), or narrowing brain fold without other appearance (4.5%). MRI changes after radiation mainly included decreased lesions and weakened enhancement (65.9%), increased and strengthened followed by decreased lesions and weakened enhancement (18.2%), and increased lesions and strengthened enhancement but with cystic change (5.7%). 9 patients were diagnosed with distinct spinal cord metastases. 31 patients received lumbar puncture, and CSF cytology mainly showed increased leukocyte counts (64.5%), evaluated protein (54.8%) and decreased glucose (51.6%). 19 patients found tumor cells and were administrated intrathecal chemotherapy (mostly methotrexate; the median cycles were 4), in which 9 turned to be negative. 4 patients received CSF genetic testing and 2 were detected mutation. 60 patients used target therapy. Patients received WBRT with boost (40 Gy in 20 fractions (f) for WBRT and 60Gy in 20 f for boost; 64.8%), focal radiation to LMs (26.2%), WBRT and CSI (50 Gy in 25 f for WBRT and 36 Gy in 20 f for CSI; 9.1%). Response rates of CR, PR, and SD were 5.7%, 71.6%, and SD 13.6%, respectively. The median follow-up and survival time was 13.5 and 17.6 months, respectively. The 1-year LC, IPFS, and OS were 75.2%, 52.9%, and 71.3%, respectively. Neuroimaging, clinical signs and CSF findings may be prior inspection items for diagnosis of LMs. Early detection with reasonable comprehensive treatment including precise radiotherapy, intrathecal chemotherapy and targeted agents can improve local control and survival time of these patients.

497 Superficial MRI-guided Laser Interstitial Thermal Therapy (LITT) for Intracranial Metastasis Is Associated With a Significantly Higher Rate of Leptomeningeal Disease

376 Laser Interstitial Thermal Therapy for Deep-Seated Perivascular Brain Tumors: Evaluating the Risk of Distal Ischemia

Surg-06. Impact Of Laser Interstitial Thermal Therapy Versus Resection For Metastases Associated With The Motor Cortex

204 Laster Interstitial Thermal Therapy for Primary and Recurrent Meningioma: A Prospective and Retrospective Multi-institutional Study

P05.24 the Diagnosis and Comprehensive Treatment of Leptomeningeal Metastases--results of a Phase II Trial

Disp-01. Factors Affecting Post-Ablation Outcomes And Trial Enrollment In Diverse Patients Undergoing Laser Interstitial Thermal Therapy

Contemporary Applications of Laser Interstitial Thermal Therapy: A Comprehensive Systematic Review

The Diagnosis and Comprehensive Treatment of Leptomeningeal Metastasis: A Phase II Trial

Laser interstitial thermal therapy in the treatment of brain metastases: the relationship between changes in postoperative magnetic resonance imaging characteristics and tumor recurrence

Laser Interstitial Thermal Therapy for First-Line Treatment of Surgically Accessible Recurrent Glioblastoma: Outcomes Compared With a Surgical Cohort

Laser interstitial thermal therapy for deep-seated perivascular brain tumors is not associated with distal ischemia

The Impact of Perilesional Heatsink Structures on Ablation Volumes in Laser Interstitial Thermal Therapy for Brain Metastases

Tmic-12. Litt Results In Robust T Cell Infiltration Within The Tumor Microenvironment In A Brain Metastasis Murine Model

Qlti-11. Predictors Of Prolonged Length Of Stay In Laser Interstitial Thermal Therapy For Intracranial Pathologies: A Single Center Experience

Surg-48. Laser Interstitial Thermal Therapy Remodels The Tumor Immune Landscape In A Mouse Glioma Model

Efficacy of laser interstitial thermal therapy for biopsy-proven radiation necrosis in radiographically recurrent brain metastases

Laser Interstitial Thermal Therapy for Posterior Fossa Lesions: A Systematic Review and Analysis of Multi-Institutional Outcomes

Effects of surgical targeting in laser interstitial thermal therapy for mesial temporal lobe epilepsy: A multicenter study of 234 patients

Surg-28. The Impact Of Perilesional Heatsink Structures On Ablation Volumes And Symmetry In Laser Interstitial Thermal Therapy For The Treatment Of Primary Central Nervous System Tumors

Magnetic resonance-guided laser interstitial thermal therapy for posterior fossa neoplasms

Safety and Efficacy of Laser Interstitial Thermal Therapy as Upfront Therapy in Primary Glioblastoma and IDH-Mutant Astrocytoma: A Meta-Analysis